ASX:NEU - NNZ-2591 in Children and Adolescents With Phelan-McDermid Syndrome

Neuren Pharmaceuticals

NNZ-2591 in Children and Adolescents With Phelan-McDermid Syndrome

Single-Group, Open-Label, Phase 2 Trial Results

NNZ-2591 in Children and Adolescents With Phelan-McDermid Syndrome | Neurology Genetics

Your question will be sent privately to Neuren Pharmaceuticals. The company may choose to make this question public.

Start the conversation

Ask Neuren Pharmaceuticals a question about this update.

Share your feedback

Discover